BioSpectrum the business of Bio & Health Sciences ASIA EDITION

Singapore announces tripartite partnership to strengthen mental healthcare

January 14, 2021 | News

The MOU outlines a shared vision to use digital technology, data and predictive analytics to help improve the mental health and well-being of the population



Holmusk has signed a Memorandum of Understanding (MOU) with Singapore's National Healthcare Group (NHG) and the Institute of Mental Health (IMH), to jointly develop innovative solutions for mental healthcare. The MOU outlines a shared vision to use digital technology, data and predictive analytics to help improve the mental health and well-being of the population.

The tripartite partnership seeks to address the unmet clinical needs of patients, populations and healthcare professionals, through leveraging the clinical expertise and translational research capabilities of NHG and IMH, and Holmusk's expertise in generating insights from mental health real-world data through advanced analytics and digital technology.

Building on its evidence generation platform (NeuroBlu) and digital therapeutics platform (mConnect), Holmusk will work closely with NHG and IMH to co-develop tools that aim to enable earlier detection and intervention in mental health disorders such as depression by using advanced analytics.

They include identifying and validating novel digital biomarkers for mental health through the use of integrated and protected data from clinical records and smartphones, which can provide a more objective measure of an individual's mental state, as well as conditions including depression and schizophrenia.

Holmusk, NHG and IMH will also co-develop a suite of digital therapeutics and tools for mental healthcare that can be used in hospitals and clinics across primary care and community settings, beginning with Major Depressive Disorder (MDD).